Roche agreed to acquire PathAI for $750 million upfront to expand AI-powered digital pathology tools for biopharma and pathology labs. The deal targets workflow and analysis capabilities that can accelerate how tissue samples are digitized and interpreted, a key enabling layer for precision oncology development. For the broader sector, the transaction reinforces how major pharma is consolidating AI infrastructure rather than building isolated tools in-house.